AVITA Medical receives FDA approval for RECELL GO next-gen skin harvesting device

AVITA Medical, Inc.

FDA approved RECELL GO next-gen autologous cell harvesting device for thermal burn wounds and full-thickness skin defects.
Device reduces training burden, improves OR workflow, and controls enzyme incubation for optimal cell yield; launch June 2024.
Clinical benefits: uses less donor skin, reduces pain, speeds closure, cuts procedures, shortens hospital stays for burns <50% TBSA.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.